Enlarge-Lung: Two-Year Follow-Up Of Real-World Patients With Locally Advanced Or Metastatic (Stage Iiib/Iv) Squamous And Non-Squamous Non-Small Cell Lung Cancer (Nsclc) From A National, Prospective, Non-Interventional Study (Nis Enlarge) Of Nivolumab After Prior Chemotherapy In Germany

Purpose: In two registrational trials, nivolumab showed overall survival (OS) benefit versus docetaxel in pretreated locally advanced or metastatic NSCLC. These results have been confirmed by initial data disclosure of the German NIS ENLARGE. Here we report mature OS data from the first 300 patients enrolled in the trial.